MM

Matthew McAviney

Partner at New Enterprise Associates (NEA)

San Francisco, California

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $2,000,000.00

  • Max Investment:

    $50,000,000.00

  • Target Investment:

    $25,000,000.00

Skills

Financial Modeling
Lifesciences
Biotechnology
Valuation
Equity Research
Corporate Development
Venture Capital
Business Development
Strategy
Medicine
Biopharmaceuticals

Education

Lists including Matthew

AH
AE
AF
AJ

Based in SF

3078 people

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Investments

AviadoBio

Series A

Total Funding: $78M

Sagimet Biosciences

Series Unknown

Total Funding: $190M

Work Experience

NE
New Enterprise Associates (NEA)

2018

  • Partner

    2018

    Biopharma

FC
F-Prime Capital

2013 - 2018

  • Principal

    2013 - 2018

    Biopharma Portfolio companies: Apellis, Avalyn, Denali, Iora, Modis, Semma, Surface, Unum

OW
Oliver Wyman

2012 - 2013

  • Associate, Health & Life Sciences Practice

    2012 - 2013

    Healthcare strategy and due diligence engagements

RW
Robert W. Baird & Co.

2011 - 2012

  • Senior Equity Research Associate, Biotechnology

    2011 - 2012

    Senior Analyst: Chris Raymond Sample coverage list: Amgen, Biogen, Celgene, Alexion, Regeneron, Biomarin, Onyx, Tesaro, Human Genome Sciences, Amag, Dendreon, Endocyte, New Link Genetics